Pizotifen (BC 105) in migraine prophylaxis.
Article Details
- CitationCopy to clipboard
Carroll JD, Maclay WP
Pizotifen (BC 105) in migraine prophylaxis.
Curr Med Res Opin. 1975;3(2):68-71. doi: 10.1185/03007997509113649 .
- PubMed ID
- 1095308 [ View in PubMed]
- Abstract
Pizotifen, an antaminic, was investigated in a double-blind placebo controlled trial to evaluate its efficacy in migraine prophylaxis. It was found to be and effective prophylactic in a proportion of migraine patients, reducing the frequency as well as the severity of headaches. Some patients showed weight gain. Several patients have continued treatment for up to 2 years with good control of their migraine and a reduction in the amount of medicament required for the acute attack.
DrugBank Data that Cites this Article
- Drugs